Article
Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients.
Pharmacogenomics - 1 Jan 2015
Pasquale Raffaella, Fenizia Francesca, Esposito Abate Riziero, Sacco Alessandra, Esposito Claudia, Forgione Laura, Rachiglio Anna Maria, Bevilacqua Simona, Montanino Agnese, Franco Renato, Rocco Gaetano, Botti Gerardo, Denis Marc G, Morabito Alessandro, De Luca Antonella, Normanno Nicola
Abstract excerpt
AIM: We assessed the ability of the Therascreen(®) kit (plasma-Therascreen) and of a peptide nucleic acids (PNA)-clamp approach to detect EGFR mutations in plasma-derived circulating-free tumor DNA (cftDNA) from non-small-cell lung cancer patients. MATERIALS & METHODS: cftDNA from 96 patients was analyzed for exon 19 deletions and the p.L858R mutation, using both plasma-Therascreen and PNA-clamp-based assays....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.